9.77

0.51% -0.05

After Hours: 9.96 0.19 +1.94%

Puma Biotechnology Inc (PBYI)

Overview News Price History Option Chain Financials Discussions Forecast

Puma Biotechnology Inc stock is traded at $9.77, with a volume of 261.52K. It is down -0.51% in the last 24 hours and up +4.83% over the past month. Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Previous Close:

$9.82

Open:

$9.9

24h Volume:

261.52K

Relative Volume:

0.77

Market Cap:

$504.33M

Revenue:

$227.18M

Net Income/Loss:

$24.38M

P/E Ratio:

20.47

EPS:

0.4774

Net Cash Flow:

$53.60M

1W Performance:

+1.77%

1M Performance:

+4.83%

6M Performance:

+54.34%

1Y Performance:

+107.87%

1-Day Range:

$9.65

$9.90

1-Week Range:

$9.02

$9.98

52-Week Range:

$4.575

$9.98

Puma Biotechnology Inc Stock (PBYI) Company Profile

Name

Puma Biotechnology Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(424) 248-6500

Address

10880 WILSHIRE BLVD., LOS ANGELES, CA

Employee

179

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

PBYI's Discussions on Twitter

Compare PBYI vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBYI Puma Biotechnology Inc	9.77	504.33M	227.18M	24.38M	53.60M	0.4774
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy
Jun-25-20	Resumed	BofA/Merrill	Underperform
Oct-08-19	Downgrade	Goldman	Neutral → Sell
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-10-19	Downgrade	Citigroup	Buy → Neutral
Jan-17-19	Initiated	Leerink Partners	Mkt Perform
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-17-18	Initiated	Goldman	Sell
May-11-18	Reiterated	Stifel	Buy
Nov-10-17	Reiterated	Citigroup	Buy
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform
Oct-02-17	Reiterated	Stifel	Buy
Sep-11-17	Reiterated	Credit Suisse	Outperform
Jul-10-17	Resumed	Leerink Partners	Outperform
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform
Mar-02-17	Reiterated	RBC Capital Mkts	Sector Perform

View All

Puma Biotechnology Inc Stock (PBYI) Latest News

Sep 25, 2026

Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates - kalkine.ca

Sep 25, 2026

Sep 18, 2026

Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer - tipranks.com

Sep 18, 2026

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins - Yahoo Finance

Sep 18, 2026

Sep 17, 2026

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer - BioSpace

Sep 17, 2026

Puma Biotechnology initiates phase II lung cancer trial By Investing.com - Investing.com Nigeria

Sep 17, 2026

Puma Biotechnology initiates phase II lung cancer trial - Investing.com

Sep 17, 2026

Puma Biotechnology Director Wilson Troy Edward Offloads 5,000 Shares at $9.10 on September 14, 2026 - Kalkine Media

Sep 17, 2026

PUMA BIOTECHNOLOGY (NASDAQ: PBYI) Director Cesano Alessandra Sells 62,150 Shares at $9.12 Following Option Exercise - Kalkine Media

Sep 17, 2026